|
|
|
|
|
|
|
|
|
|
|
|
|
28.09.26 - 22:06
|
Definium Therapeutics Announces New Employee Inducement Grants (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to fifteen newly hired non-executive employees consisting of options to purchase an aggregate of 334,810 common shares of the Company (the "Options") with effective grant dates of September 28, 2026. The Options have an exercise price equal to the closing price of Definium's common shares on the date of the grants, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee's continued employment.
The Options were granted as a material inducement to each employee's employment and were approved by Definiu...
|
|
|
|
|
|
|
|
|
|
|
|
|
14.09.26 - 12:03
|
Definium Therapeutics Announces New Employee Inducement Grants (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 56,650 common shares of the Company (the "Options") with effective grant dates of September 14, 2026. The Options have an exercise price equal to the closing price of Definium's common shares on the date of the grants, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee's continued employment.
The Options were granted as a material inducement to each employee's employment and were approved by Definium'...
|
|
|
|
|
31.08.26 - 22:03
|
Definium Therapeutics Announces New Employee Inducement Grants (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 88,900 common shares of the Company (the "Options") with effective grant dates of August 31, 2026. The Options have an exercise price equal to the closing price of Definium's common shares on the date of the grants, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee's continued employment.
The Options were granted as a material inducement to each employee's employment and were approved by Definium's C...
|
|
|
17.08.26 - 22:06
|
Definium Therapeutics Announces New Employee Inducement Grants (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 32,900 common shares of the Company (the "Options") with effective grant dates of August 17, 2026. The Options have an exercise price equal to the closing price of Definium's common shares on the date of the grants, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee's continued employment.
The Options were granted as a material inducement to each employee's employment and were approved by Definium's Com...
|
|
|
12.08.26 - 18:15
|
XFRA: MMQ0: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
DEFINIUM THERAP.INC. O.N. MMQ0 CA24477V1058
AB/FROM ONWARDS 12.08.2026 17:58 CET...
|
|
|
|
|
|
|
12.08.26 - 13:48
|
XFRA: MMQ0: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
DEFINIUM THERAP.INC. O.N. MMQ0 CA24477V1058 BAW/UFN...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
